← Back to headlines
H.C. Wainwright Reaffirms 'Buy' Rating for Vanda Pharmaceuticals (VNDA)
H.C. Wainwright has maintained its 'Buy' rating for Vanda Pharmaceuticals (VNDA), citing specific reasons for its continued positive outlook. The firm's analysis suggests the stock remains an attractive investment.
3 Jul, 13:13 — 3 Jul, 13:13
Sources
Showing 1 of 1 sources
